Skandinaviska Enskilda Banken (SEB)’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-89,502	Closed	-$376K	–	1002
2023 Q1	$376K	Sell	89,502 -4,401	-5%	-$22.8K	﹤0.01%	793
2022 Q4	$564K	Sell	93,903 -5,442	-5%	-$29.7K	﹤0.01%	722
2022 Q3	$578K	Buy	+99,345	New	+$619K	﹤0.01%	739

Other funds holding CTIC

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s CTIC Position: Q2 2023 in Review

Skandinaviska Enskilda Banken (SEB) sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 89,502 shares — an estimated $376K sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in CTIC in Q3 2022 and held it in 3 quarters. The position peaked at $578K in Q3 2022. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

Skandinaviska Enskilda Banken (SEB) reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
Skandinaviska Enskilda Banken (SEB) sold 89,502 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $376K.
Skandinaviska Enskilda Banken (SEB) first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q3 2022 and held it in 3 quarters.
Skandinaviska Enskilda Banken (SEB)'s CTI BioPharma Corp. (DE) Common Stock position peaked at $578K in Q3 2022.
2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q2 2023, filed 7 Aug 2023.